What Genomind's Genecept Assay covers, how it's priced, and how it compares to Gene2Rx for direct-to-consumer pharmacogenetic testing.
Last updated: 2026-04-22
| Feature | Gene2Rx | Genomind |
|---|---|---|
| Price to the patient | $5 to $49 depending on report tier | Highly variable. Insured patients often a few hundred dollars out-of-pocket; uninsured or denied claims can run much higher |
| Doctor's order required | No, direct-to-consumer | Yes, a healthcare provider must order the test |
| Uses existing 23andMe, AncestryDNA, or WGS data | Yes, upload your raw data | No, requires a new cheek swab |
| Turnaround time end-to-end | Minutes after upload | Lab results typically 3 to 5 business days; end-to-end workflow with appointments and sample shipping is 2 to 4 weeks |
| Medications reported on | 103 across every major drug class | Approximately 130 medications across psychiatry, neurology, and some chronic pain and cardiology |
| Genes tested | CYP2D6, CYP2C19, CYP2C9, CYP3A5, CYP2B6, CYP1A2, SLCO1B1, VKORC1, DPYD, TPMT, UGT1A1, HLA-B, HLA-A | CYP2D6, CYP2C19, CYP2C9, CYP3A4, CYP1A2, CYP2B6, plus SLC6A4, COMT, MTHFR, DRD2, ADRA2A, MC4R, UGT2B15, OPRM1, BDNF, HLA-B |
| Primary clinical focus | Comprehensive pharmacogenetics across psychiatry, cardiology, pain, oncology, and more | Psychiatry, neurology, and chronic pain |
| Report format | Evidence-graded per drug (Strong / Moderate / Optional) traceable to CPIC and FDA guidelines | Color-coded categories combined with a psychiatric-framed report tailored to mental health prescribing |
| Non-CPIC neuropsychiatric markers | Not included (CPIC has not issued guidelines for MTHFR, SLC6A4, COMT, DRD2) | Included and highlighted as differentiators |
| Insurance billing | Not applicable, direct pay | Files with insurance |
Genomind is a company that markets pharmacogenetic testing to mental health providers. Its flagship product historically was the Genecept Assay, and more recent iterations have been released under the Genomind Professional PGx Express name. All versions target essentially the same audience: psychiatrists, psychiatric nurse practitioners, and primary care clinicians managing complex or treatment-resistant psychiatric patients.
The test is a cheek-swab sample collected in a provider's office (or mailed to the patient at the provider's direction), shipped to Genomind's lab, analyzed, and returned to the ordering clinician. The report is specifically formatted for psychiatric prescribing, with medication categorizations designed to slot into treatment decisions. Genomind's sales and education organization is oriented around making the report useful inside a psychiatric practice.
Genomind's pricing is hard to pin down in advance because it depends on your insurance. For insured patients whose insurance accepts the claim, out-of-pocket costs often land in the few-hundred-dollar range after insurance adjustment. For uninsured patients, or for those whose insurance denies the claim because of diagnosis requirements, the cost can be much higher, in some cases exceeding a thousand dollars.
Gene2Rx is direct pay at $5 to $49. The difference reflects business model, not analytical quality. Clinical tests like Genomind fund sample collection, FDA-compliant lab processing, insurance billing infrastructure, sales representatives, and clinician-facing education. Gene2Rx skips most of that by analyzing genetic data you already own and by operating as an informational service rather than as a new clinical lab test.
Yes. Genomind's tests are provider-ordered. You cannot purchase the test directly from Genomind as a consumer. Your prescribing clinician must initiate the order, authorize sample collection, and receive the results. For many Genomind customers this is not a barrier because they are already in the care of a psychiatrist who is familiar with the test. For patients without an active mental health prescriber, or whose doctor is not comfortable with pharmacogenetic testing, access can be a problem.
Gene2Rx does not require a prescriber. You upload genetic data you already have, pay for the report tier you want, and receive the report. Sharing the results with a clinician afterward is encouraged, but the ordering flow does not depend on one.
Genomind's marketing emphasis is on genes outside the standard drug-metabolizing panel: SLC6A4 (serotonin transporter), DRD2 (dopamine D2 receptor), ADRA2A (alpha-2 adrenergic receptor), COMT (catechol-O-methyltransferase), MTHFR (folate methylation), MC4R (melanocortin receptor), OPRM1 (mu-opioid receptor), and BDNF (brain-derived neurotrophic factor). The pitch is that these genes provide insight into psychiatric drug response beyond what pharmacokinetic metabolizer genes can explain.
The pharmacogenetics research community is divided on how actionable these markers actually are. The Clinical Pharmacogenetics Implementation Consortium (CPIC) publishes evidence-graded, peer-reviewed drug-gene guidelines, and the neuropsychiatric markers Genomind emphasizes do not have CPIC dosing guidelines. The American College of Medical Genetics and Genomics (ACMG) and the College of American Pathologists (CAP) have explicitly recommended against MTHFR genotyping for most clinical indications, because the evidence does not support using MTHFR variants to guide prescribing decisions.
Gene2Rx does not report on SLC6A4, DRD2, COMT, MTHFR, ADRA2A, MC4R, OPRM1, or BDNF. That is a deliberate choice: we report on genes with actionable CPIC or FDA guidelines. If you specifically want non-CPIC markers in your report, Genomind covers them; Gene2Rx does not. Reasonable people make this call differently, and we are not trying to hide that difference.
Genomind's panel covers roughly 130 medications across psychiatry, neurology, some chronic pain, and selected cardiology drugs. This is broader than GeneSight's psychiatric-only panel but narrower than a fully comprehensive pharmacogenetic profile. Genomind does not report on several clinically important non-psychiatric drug categories including most chemotherapy drugs, several immunosuppressants, and some infectious-disease drugs.
Gene2Rx covers 103 medications across every major therapeutic class where CPIC or FDA has published pharmacogenetic guidance. The list includes psychiatric medications plus cardiology (clopidogrel, warfarin, metoprolol), chemotherapy (capecitabine, fluorouracil, tamoxifen, mercaptopurine, azathioprine, irinotecan), immunosuppressants (tacrolimus), infectious disease (abacavir, efavirenz, voriconazole), gastrointestinal (omeprazole and other PPIs), pain management (codeine, tramadol, NSAIDs, tricyclic antidepressants used for pain), and anticonvulsants (carbamazepine, phenytoin, brivaracetam).
Both services will tell you your CYP2D6 and CYP2C19 metabolizer phenotype. The practical difference is which medications get walked through in the report.
A Genomind report is built for psychiatric prescribing workflow. Results are organized around mental health medication decisions with recommendations framed for that audience. For a psychiatrist running treatment-resistant depression or complex medication management, the framing is useful because it matches how they think about prescribing.
Gene2Rx reports are built around the underlying CPIC and FDA guidelines. Each drug's recommendation is paired with an evidence level (Strong, Moderate, or Optional) and the specific phenotype-level guidance from published guidelines. The presentation is closer to what a clinical pharmacist or pharmacogenomics specialist would want to see. It is less tailored to psychiatric workflow and more aligned with general clinical pharmacogenetic practice.
Both services rely on the same underlying clinical guidelines for the core drug-metabolizing enzymes (CYP2D6, CYP2C19, etc.): CPIC peer-reviewed guidelines and the FDA Table of Pharmacogenetic Associations. For the core genes, the evidence is robust across decades of research.
For Genomind's additional neuropsychiatric markers, the evidence base is thinner. Several genes in Genomind's panel have been evaluated in studies, but the results have been mixed and the markers have not been incorporated into CPIC's formal dosing guidelines. Genomind points to company-funded outcome studies and its internal curation of research; critics point to the lack of independent guideline adoption. This does not mean Genomind's expanded panel is wrong; it means the clinical actionability of its differentiators is less established than the core metabolizer genes.
Genomind can be a reasonable choice for specific patients. If you are working with a psychiatrist who specifically uses Genomind in their treatment-resistant depression practice, the report will fit cleanly into their workflow. If you have insurance that covers Genomind and your out-of-pocket cost will be within your budget, the insurance-billed model is convenient. If you specifically want a report that includes the neuropsychiatric markers (SLC6A4, COMT, MTHFR, DRD2) that Genomind emphasizes, Gene2Rx will not include those and Genomind will.
The situations where Gene2Rx is usually a better fit: you already have 23andMe or AncestryDNA data, you want pharmacogenetic information for medications outside the psychiatric and neurological focus, you prefer guideline-anchored reporting over company-curated interpretations, you are uninsured or do not want to navigate insurance, or you want the report quickly and cheaply with the option to discuss it with your clinician on your own timeline.
For the core pharmacogenetic content, yes. Both tests report the same CYP2D6, CYP2C19, CYP2C9, and related metabolizer phenotypes using the same CPIC and FDA guidelines. The practical differences: Gene2Rx is direct-to-consumer and costs $5 to $49, Genomind requires a prescriber and typically costs several hundred dollars with insurance. The one thing Gene2Rx does not provide that Genomind does is the extended neuropsychiatric panel (SLC6A4, COMT, MTHFR, etc.), which has less established clinical actionability but is part of Genomind's value proposition.
The American College of Medical Genetics and Genomics (ACMG) and the College of American Pathologists (CAP) have explicitly recommended against routine MTHFR genotyping for most clinical indications, because the research does not support using MTHFR variants to guide prescribing or supplementation decisions. Genomind includes MTHFR in its panel and presents it as informative. Gene2Rx does not include MTHFR because CPIC has not published actionable guidelines for it. Reasonable clinicians disagree about the value of MTHFR testing.
Genomind's panel covers around 130 medications, mostly concentrated in psychiatry and neurology. Gene2Rx's panel covers 103 medications with deeper coverage across non-psychiatric drug classes like cardiology, chemotherapy, immunosuppressants, and gastroenterology. Neither is strictly broader than the other. The relevant question is which medications matter for you.
Yes. If you have already taken Genomind (or any clinical pharmacogenetic test) and you want pharmacogenetic information for non-psychiatric medications that Genomind does not cover, Gene2Rx can interpret your existing 23andMe or AncestryDNA data to fill the gaps. Your underlying metabolizer phenotype is the same regardless of which test analyzes it, so combining Genomind's psychiatric-focused report with Gene2Rx's broader coverage is a valid use of both.
Gene2Rx analyzes genetic data you already have from consumer genotyping services rather than performing a new clinical lab test. That removes the largest cost drivers of tests like Genomind: cheek-swab kits and sample shipping, FDA-compliant lab processing of a new sample, insurance billing infrastructure, sales representatives who call on clinicians, and clinician-facing education. The underlying pharmacogenetic interpretation is comparable in cost regardless of where the genotype data came from.
Genomind covers HLA-B markers relevant to carbamazepine and a few other drugs. Gene2Rx also covers HLA-B for abacavir and carbamazepine. Both services will flag HLA-B*57:01 (abacavir hypersensitivity) and HLA-B*15:02 (carbamazepine Stevens-Johnson syndrome in at-risk populations) if your genotype indicates risk. This category of pharmacogenetics is particularly well-established and every reputable PGx test covers it.
If you already have 23andMe, AncestryDNA, MyHeritage, or whole-genome data, Gene2Rx turns it into a comprehensive pharmacogenetic report. CPIC-anchored, direct-to-consumer, no doctor required. Starting at $5.
Get your Gene2Rx report Look up a medication firstInformational only, not medical advice. Every pharmacogenetic test has a role; the right choice depends on your situation, insurance, and the medications you're evaluating. Always discuss pharmacogenetic results with your prescribing clinician before making any medication change.